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Duchenne muscular dystrophy (DMD) is one of the most severe X-linked, inherited diseases of childhood, characterized by progressive muscle
wasting and weakness as the consequence of mutations in the dystrophin gene. The protein encoded by dystrophin is a huge cytosolic protein that
links the intracellular F-actin filaments to the members of the dystrophin–glycoprotein–complex (DGC). Dystrophin deficiency results in the
absence or reduction of complex components that are degraded through an unknown pathway. We show here that muscle degeneration in a
Caenorhabditis elegans DMD model is efficiently reduced by downregulation of chn-1, encoding the homologue of the human E3/E4
ubiquitylation enzyme CHIP. A deletion mutant of chn-1 delays the cell death of body-wall muscle cells and improves the motility of animals
carrying mutations in dystrophin and MyoD. Elimination of chn-1 function in the musculature, but not in the nervous system, is sufficient for this
effect, and can be phenocopied by proteasome inhibitor treatment. This suggests a critical role of CHIP/CHN-1-mediated ubiquitylation in the
control of muscle wasting and degeneration and identifies a potential new drug target for the treatment of this disease.
© 2007 Elsevier Inc. All rights reserved.Keywords: Caenorhabditis elegans; Duchenne muscular dystrophy; E3-ligase; Protein degradation; ProteasomeIntroduction
Protein degradation by the ubiquitin–proteasome system
(UPS) is very active in muscle cells, both under physiological
and disease conditions (Lecker et al., 1999). Ubiquitylation
requires the concerted activity of a number of components that
include E1 (ubiquitin-activating enzyme), E2 (ubiquitin-con-
jugating enzymes), E3 (ubiquitin ligases) and, as recently
established, E4 (an additional ubiquitin-conjugating factor,
UFD2) enzymes (Koegl et al., 1999; Pickart and Eddins, 2004).⁎ Corresponding author. Bio 3, Bioinformatics and Molecular Genetics
(Faculty of Biology) and ZBMZ – Center for Biochemistry and Molecular Cell
Research (Faculty of Medicine), Schaenzlestr. 1, D-79104 Freiburg, Germany.
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doi:10.1016/j.ydbio.2007.09.033CHN-1/CHIP (carboxyl-terminus of Hsc-70 interacting protein)
is an E3/E4 ubiquitylation enzyme that is strongly expressed in
both the nervous system and musculature (Ballinger et al.,
1999). The human protein has been identified as an interactor of
parkin, an E3 ubiquitin ligase associated with hereditary
variants of Parkinson's disease (Imai et al., 2002).
The cause of muscle degeneration in Duchenne muscular
dystrophy is still enigmatic. Degradation is triggered by the loss
of dystrophin, although in several experimental models of
dystrophin deficiency, muscle activity is only gradually lost
(Bessou et al., 1998; Bulfield et al., 1984). The encoded
dystrophin protein is a huge cytosolic protein that links the
intracellular F-actin filaments to the members of the dystro-
phin–glycoprotein–complex (DGC) (Ervasti and Campbell,
1991; Ervasti and Campbell, 1993). Mutations in the C. elegans
dystrophin orthologue dys-1 result in a mild movement defect
and some other subtle phenotypic aspects not immediately
explained by muscle degeneration (Bessou et al., 1998). In
194 O. Nyamsuren et al. / Developmental Biology 312 (2007) 193–202agreement with the double mutant in the mouse, an additional
mutation in the gene hlh-1, which is an orthologue of the human
MyoD, strongly enhanced the phenotype of dys-1 mutant
animals (Gieseler et al., 2000). Whereas dys-1; hlh-1 mutants
move well in early development until the fourth larval stage
(L4), adult animals suffer from paralysis (see Fig. 1; Supple-
mental Movie 1) that could be due to activation of the
ubiquitylation/proteasome system in muscles.
We recently identified UNC-45, an evolutionary conserved
muscle co-chaperone, as a substrate of a novel E3/E4 complexFig. 1. Suppression of motility and muscle degeneration defects of dystrophic worm
backgrounds. P values indicate comparisons to dys-1(cx18), ∗∗Pb0.01 and to dys-
mean (SEM). (b) Phalloidin staining of actin filaments of the wild type (top), dys-1
animals (bottom). See Fig. 3 for the phalloidin staining of the other strains tested. All
experiment. Dorsal view. Scale bar: 50 μm.consisting of CHN-1/CHIP and the E4 enzyme UFD-2 (Hoppe
et al., 2004). Both UNC-45 and CHIP in humans have been
implicated in myogenesis, and the CHIP/UFD-2/p97 complex
regulates UNC-45-dependent myosin assembly and links UNC-
45 turnover to myopathy (Janiesch et al., 2007). No other
substrates of CHN-1/CHIP have been identified in striated
muscles so far. However, we reasoned that CHN-1/CHIP could
be part of a general protein turnover mechanism that is activated
in response to an intracellular increase in misfolded proteins or
through the liberation of protein subunits after protein complexs by chn-1 mutation. (a) Food race experiment of animals with different genetic
1(cx18); hlh-1(cc561), ∗∗∗Pb0.001. Error bars represent standard error of the
(cx18); hlh-1(cc561ts) (middle) and chn-1(by155) dys-1(cx18); hlh-1(cc561ts)
animals were maintained at 15 °C and were second-day adult at the time point of
Table 1
Food race assay of second-day adult animals
% Animals that reached the food source [mean±SEM]
Genotype 10 min a 20 min 30 min 1 h 2 h
Wild type 7.8±3.8 54.5±19.5 79.6±23.5 97.6±2.3 100.0±0.0
chn-1 0.0±0.0 27.9±22.9 58.0±25.0 86.0±8.8 98.2±0.1
dys-1 4.5±2.1 27.7±8.0 41.6±4.8 58.7±3.6 72.8±1.6
chn-1 dys-1 7.4±5.2 22.5±5.0 39.6±4.4 64.2±3.5 86.9±3.8 ⁎
hlh-1 3.6±2.5 21.1±10.6 45.1±13.2 64.5±8.8 75.1±6.4
chn-1; hlh-1 0.0±0.0 4.3±3.0 17.6±4.7 49.8±4.4 73.0±4.4
dys-1; hlh-1 0.0±0.0 0.9±0.5 1.7±0.5 5.2±2.2 21.0±3.9
chn-1 dys-1;
hlh-1
1.2±0.3 17.2±4.1 41.0±1.9 65.9±1.9 82.2±1.7 ⁎⁎
Full strain designations: chn-1: chn-1(by155). dys-1: dys-1(cx18). chn-1 dys-1:
chn-1(by155) dys-1(cx18). hlh-1: hlh-1(cc561). chn-1; hlh-1: chn-1(by155);
hlh-1(cc561). dys-1; hlh-1: dys-1(cx18); hlh-1(cc561). chn-1 dys-1; hlh-1: chn-
1(by155) dys-1(cx18); hlh-1(cc561).
Numbers are mean values of at least 2 replicates.
a Duration of the experiment.
⁎ Pb0.01: chn-1(by155) dys-1(cx18) compared to dys-1(cx18).
⁎⁎ Pb0.001: chn-1(by155) dys-1(cx18); hlh-1(cc561) compared to dys-1
(cx18); hlh-1(cc561).
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mutation, as well as interference with the proteasome system by
treatment with the non-specific proteasome inhibitor MG132,
indeed slows the progress of muscular dystrophy in the C.
elegans DMD model.
Results and discussion
The chn-1(by155) mutant is healthy and does not display a
pronounced phenotype (Hoppe et al., 2004). To test whether
CHN-1 function is involved in muscle degradation, we
generated chn-1 dys-1; hlh-1 triple mutant animals. Already,
when inspected through the dissecting microscope, adult
animals with this genotype moved considerably better than
the dys-1; hlh-1 double mutants that served as a control
(Supplementary Movies 1 and 2). In order to quantitate this
observation, we tested the motility of the different C. elegans
strains in a food race assay and also measured the speed of
individual animals directly. For the food race, the number of
animals that within 2 h reach their Escherichia coli food source
on a 9-cm Petri dish, was counted. Only a minor percentage
([mean±SEM] 21.0±3.9% compared to wild type) of dys-1;
hlh-1 double mutants covered the 9-cm track during the
experiment, as a result of the dystrophic body-wall musculature.
In contrast, more than 80% (82.2±1.7%) of the chn-1 dys-1;
hlh-1 triple mutants reached the food, indicating a strikingly
more active musculature (Fig. 1a). Since in both mouse and C.
elegans models of DMD muscle degeneration is much more
pronounced in dystrophin/MyoD double mutants (Gieseler et
al., 2000; Megeney et al., 1999) compared to the single alleles,
we tested all combinations of mutants in C. elegans in order to
analyse whether the chn-1 mutation suppresses dys-1 or hlh-1
aspects of the phenotype. Both hlh-1 and dys-1 single mutants
showed slight but significant reduction of motility compared to
the wild type. Only the motility defect of dys-1mutant ([mean±
SEM] 72.8±1.6% vs. 86.9±3.8%), but not the phenotype of the
hlh-1 mutant (75.1±6.4% vs. 73.0±4.4%) was suppressed by
the chn-1 mutation (Fig. 1a; Table 1), corroborating the
previously described suggestion that the temperature-sensitive
hlh-1 mutation that only has a very mild phenotype at 15 °C,
enhances dys-1/dystrophin mutants (Gieseler et al., 2000).
Thus, chn-1 suppression involves a mechanism directly related
to dys-1 dysfunction.
To verify this result, we used a computerized image analysis
system (DIAS) to analyze the movement of individual animals
of each genotype at 15 °C. Movements of arbitrarily chosen
single animals on a NGM plate without bacteria were recorded
for an interval of 10 s with a digital video camera attached to a
dissecting microscope. The results are shown in Fig. 2. Animals
with a dys-1; hlh-1 genotype move at 43.1 μm/s (±1.7 μm/s),
whereas chn-1 dys-1; hlh-1 triple mutants move with almost
twice the speed (71.7±2.4 μm/s). These data indicate that
downregulating chn-1 activity improves the motility of the
DMD animals.
Several attempts have been made in the past to reduce or
abolish muscle degeneration in DMD. All of them relied on
either blocking the dystrophic pathology by denervation or byimpairing the contraction of the muscles, and, thus, required
massive immobilization of the muscles (Mariol et al., 2007). A
systematic assessment recently revealed that the physical
constraints exerted on the muscle fibers during contraction are
responsible for turning the lack of dystrophin into progressive
muscle degeneration (Mariol et al., 2007). Consistently,
mutations that impaired the excitation–contraction cascade on
both neuronal and muscular levels was sufficient to reduce
muscle degeneration in dys-1; hlh-1 animals. Our result provide
a notably different mechanistic way to reduce muscle
degeneration, because downregulation of chn-1 did not reduce,
but actually improved motility of dys-1; hlh-1 animals almost
twofold. This suggests that elimination of chn-1 is beneficial
even under conditions when physical tension of the muscles is
maintained.
Next, we confirmed the mechanism of suppression at the
cellular level. Phalloidin staining of the actin filaments revealed
that all 95 body-wall muscle cells are stained uniformly in wild
type animals. In the dys-1; hlh-1 double mutants, a variable
number of muscle cells lacked actin filament staining (Fig. 1b).
An average of 12.4% (±0.3%) of the muscles did not display
any staining, corroborating previous results (Gieseler et al.,
2000). In the chn-1 dys-1; hlh-1 triple mutants, this number was
reduced to 4.2% (±0.1%) (Fig. 1b; Table 2). This result is
consistent with the decreased motility phenotype and confirms
the suppressor activity of CHN-1/CHIP in the C. elegans
muscles. None of the other mutants, except the dys-1 mutants,
which showed a slight muscle degeneration (Fig. 3, see arrow;
Table 2), revealed abnormal actin patterning. This slight muscle
degeneration in dys-1 mutants was not observed in chn-1 dys-1
double mutants, suggesting that the chn-1 mutation specifically
suppresses the phenotype of dys-1.
Since the muscular dystrophy in dys-1; hlh-1 mutants is
most pronounced starting from the late developmental stage L4,
during the most intensive net increase in muscle volume, chn-1
mutants could in principle have a heterochronic suppressor
Table 2
Body-wall muscle cell count of second-day adult animals
Genotype % of abnormal body-wall
muscle cells [mean±SEM]
n
Wild type 0.0±0.0 15
chn-1 0.0±0.0 15
dys-1 0.4 a±0.04 Pb0.001 vs. chn-1 dys-1 12
chn-1 dys-1 0.0±0.0 15
hlh-1 0.0±0.0 15
chn-1; hlh-1 0.0±0.0 15
dys-1; hlh-1 12.4±0.3 14
chn-1dys-1; hlh-1 4.2±0.1 Pb0.001 vs. dys-1; hlh-1 34
Full strain designations: chn-1: chn-1(by155). dys-1: dys-1(cx18). chn-1 dys-1:
chn-1(by155) dys-1(cx18). hlh-1: hlh-1(cc561). chn-1; hlh-1: chn-1(by155);
hlh-1(cc561). dys-1; hlh-1: dys-1(cx18); hlh-1(cc561). chn-1 dys-1; hlh-1: chn-
1(by155) dys-1(cx18); hlh-1(cc561).
n – number of animals tested.
a 1 body-wall muscle cell was missing in 5 of 12 animals (see Fig. 3, arrow).
Fig. 2. Suppression of motility defects of dystrophic worms by mutants of
chn-1 interactor genes. The motility of second-day adult animals with dif-
ferent genetic backgrounds was analyzed. Full strain designations: chn-1 dys-1;
hlh-1: chn-1(by155) dys-1(cx18); hlh-1(cc561). dys-1; hlh-1: dys-1(cx18);
hlh-1(cc561). dys-1; hlh-1 ufd-2: dys-1(cx18); hlh-1(cc561) ufd-2(tm1380).
dys-1; hlh-1; pdr-1(tm395): dys-1(cx18); hlh-1(cc561); pdr-1(tm395). dys-1;
hlh-1 pdr-1(lg103): dys-1(cx18); hlh-1(cc561ts); pdr-1(lg103). P values refer to
comparisons with dys-1(cx18); hlh-1(cc561). ns, not significant (P≥0.05),
∗∗Pb0.01, ∗∗∗Pb0.001. Error bars represent standard error of the Mean
(SEM).
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test such a model, we carefully examined muscle development
in the distinct genetic backgrounds using muscle-specific
markers and developmentally synchronised animals. The
generation time and development of dys-1; hlh-1 mutant
animals was indistinguishable from the chn-1 dys-1; hlh-1
triple mutants, indicating that chn-1mutation does not affect the
timing of development. For a more detailed analysis of
individual cells, we observed the generation and pathology of
all 95 body-wall muscle cells in a number of animals of each
genotype. Both in the double and triple mutant combinations,
the overwhelming majority of the 95 muscle cells was present in
the late larval stages (L3/L4), and began to degenerate in young
adult dys-1; hlh-1 animals (6 days at 15 °C), but to a much
lesser extent in chn-1 dys-1; hlh-1 mutant animals. The
degeneration in the presence of wild type chn-1 coincides
with the timing of the strong increase of chn-1 expression that
can be observed between L4 and adulthood (Janiesch et al.,
2007). We found that several steps in this degradation process
were superficially similar to the sarcopenia that had been
observed in C. elegans wild type animals in their mid- and late-
life (days 9–20 at 20 °C; Herndon et al., 2002), but had
previously not been described for the dys-1; hlh-1 animals.
Using a muscle specific nuclearly localized GFP marker (Fire etal., 1998), we first noted a decrease in the GFP staining of
transgenically labelled nuclei in 6-day-old animals at 15 °C
(Fig. 4b). At higher resolution, we found that this loss may
reflect a change in the distribution of the nuclear localization of
GFP. In the mid-part of the body, the nuclei of cells that later lost
actin staining disappeared completely (Fig. 4b), many nuclei
lost their shape (Fig. 4e) and nucleolus size increased relatively
to the nuclear size (Fig. 4f). Using a myo-3∷gfp fusion-protein
localized to the sarcomeres of body-wall muscles (Campagnola
et al., 2002), we observed fraying of individual sarcomeres, and
some cells seemed to fully disintegrate at various positions
(Figs. 5b–d). In contrast, at the anterior and posterior end of the
body muscle, cells generally looked inconspicuous and only
occasionally were lost. In the mid-body region, several cells
also accumulated intracellular vesicles typical for lysosomal
disintegration (Fig. 6, arrows) seen during necrosis (Syntichaki
and Tavernarakis, 2002), and their membranes detached from
that of other muscle cells (Fig. 6, arrowheads). The number of
anomalies was considerably lower in chn-1 dys-1; hlh-1 mutant
animals (Fig. 3c; Figs. 5e, f), suggesting that chn-1mutation is a
potent suppressor of dys-1; hlh-1 muscle cell necrosis in C.
elegans.
Dystrophin expression in C. elegans and other organisms is
not restricted to the musculature, but is also detectable in
neuronal cells and the reproductive system (McKay et al.,
2003). Similarly, both chn-1 in C. elegans and CHIP in humans
are expressed in both neurons and muscles (Hoppe et al., 2004).
Downregulation of neuronal gene expression has been shown to
ameliorate DMD phenotypes by reducing the innervation of
muscle contraction (Karpati et al., 1988; Mariol et al., 2007),
and recent results in a transgenic mouse model of bulbar
muscular atrophy suggested that a high level of CHIP
expression ameliorated the phenotype caused by the expansion
of the polyglutamine tract within the androgen receptor (Adachi
et al., 2007). In order to identify the cellular specificity of the
CHN-1/CHIP suppressor activity, we generated transgenic
animals expressing the chn-1 gene in individual tissues, and
tested whether cell-type-specific expression can rescue the
suppression of muscle degeneration. Expression of transgenic
Fig. 3. Phalloidin staining of actin filaments in second-day adult mutant animals. All mutants except dys-1(cx18) show normal body-wall muscle structure: (a) chn-1
(by155); (b) dys-1(cx18), the arrow indicates the body-wall muscle cell which shows no actin filament staining; (c) chn-1(by155) dys-1(cx18), the abnormality seen in
dys-1(cx18) mutants was suppressed by chn-1 mutation; (d) hlh-1(cc561ts) and (e) chn-1(by155) hlh-1(cc561ts). All mutants are maintained at 15 °C. Dorsal view.
Scale bar: 50 μm.
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the motility and phenotype of chn-1 dys-1; hlh-1 triple mutant
animals, whereas expression of the same transgene from the
myosin promoter unc-54 specific for muscle cells resulted in
significantly reduced motility (Fig. 7). This indicates a solid
rescue of mutant chn-1 suppressor activity. We conclude that
muscle-specific reduction of CHN-1 activity is sufficient to
prolong the integrity and function of dystrophin mutant animals.
Since wild type activity of chn-1 facilitates muscle
degeneration in the DMD model, whereas mutant chn-1 does
not, we wondered to which cellular function CHN-1/CHIP
might contribute that promotes deprivation of dystrophy–
mutant muscles. CHIP acts as an E3 ligase with chaperone-like
function, and is part of the cellular quality control with the
ability to degrade misfolded proteins in association with heat-
shock chaperones (Rosser et al., 2007). Only few substrates of
CHIP have so far been identified, and the available functional
data suggest that it may either promote proper folding of
unfolded proteins or target them for ubiquitylation and
proteasome-dependent degradation. The latter function would
suggest that the administration of a proteasomal inhibitor should
phenocopy the inactivation of chn-1 in the dys-1; hlh-1 double
mutant. MG132 is a proteasomal inhibitor that, at higher
concentrations, is lethal for C. elegans due to blocking
proteasomal degradation. We therefore tested pharmacological
treatment of dys-1; hlh-1 worms with different, sublethal
concentrations of MG132 and monitored the motility of animals
in food race experiments. When treated with the diluent (1%
DMSO), 91.1% (±5.0%) of the wild type animals and 9.9%
(±4.0%) of the dys-1; hlh-1 animals reached the food source.
Addition of 200 μM and 500 μM MG132, respectively, to the
medium did not alter the behavior of wild type (89.6±1.5% at
200 μM MG132; 92.8±0.7% at 500 μM MG132), but resulted
in increasing numbers of double mutants that were able to cover
the track (32.9±2.3% at 200 μM MG132; 31.1±2.9% at500 μM MG132) (Fig. 8). Concentrations higher than 1 mM
severely impaired worm behaviors and were not considered
further (data not shown). We conclude from these experiments
that MG132 can phenocopy the suppression obtained by
downregulating chn-1 expression. Despite of the toxicity of
the compound at higher concentrations, low doses of MG132
actually helped to improve the motility of the dys-1; hlh-1
animals. These data also suggest that inactivation of chn-1
prevents proteasomal degradation of unstable proteins in the
dys-1 mutant muscles. Our results are consistent with previous
reports suggesting that inhibition of the proteasome using the
proteasome inhibitor MG132 rescued the protein localization of
the members of the DGC and ameliorated the histopathological
aspects of muscular dystrophy (Bonuccelli et al., 2003).
Our results are consistent with a role of CHN-1/CHIP in
removing defective or misfolded proteins in the musculature.
We had previously shown that UNC-45, a muscle-specific co-
chaperone, is ubiquitylated through a CHN-1-dependent
process (Hoppe et al., 2004). UNC-45 activity is required for
the assembly of the myosin thick filament during development,
and a CHN-1/UFD-2/CDC-48 complex is involved in both
myosin assembly and degradation (Janiesch et al., 2007). A
role of wild type UNC-45 in the degradation of muscles has
not been shown so far. However, the CDC-48/UFD-2/CHN-1
complex could target another, yet unidentified substrate in
dystrophic muscles or could participate in a protein complex
with a different composition that mediates substrate specificity.
If the first assumption were true, then mutations in ufd-2
should also result in suppression of dys-1; hlh-1. This is,
however, not the case. The dys-1(cx18); hlh-1(cc561) ufd-2
(tm1380) triple mutant behaved indistinguishable from the
dys-1; hlh-1 double mutant, indicating that the muscle
degeneration in dystrophin mutants involves a mechanism to
which CHN-1/CHIP selectively contributes, whereas UFD-2
does not (Fig. 2).
Fig. 4. Degradation of muscle cell nuclei in dystrophin-deficient worms. Transgenic expression of a nuclear localized GFP was monitored in various genetic
backgrounds. Whole-animal view of C. elegans expressing GFP in body-wall muscle nuclei: (a) wild type; (b) dys-1(cx18); hlh-1(cc561), disappearance of nuclei in
the mid-part of the body; (c) chn-1(by155) dys-1(cx18); hlh-1(cc561). Ventral view. (d–f) Magnified view of muscle nuclei: (d) wild type; (e, f) dys-1(cx18); hlh-1
(cc561), changes in nucleus shape and increase of nucleolus size relative to nucleus. All animals were maintained at 15 °C and were second-day adults at the time point
of experiment.
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an E3 ligase implicated in Parkinson's disease. Our previous
results had shown that the C. elegans parkin orthologue, PDR-
1, forms a protein complex with CHN-1 involved in protein
ubiquitylation (Springer et al., 2005). Like chn-1, pdr-1 is also
expressed in both neurons and the musculature. Two classes of
parkin mutants had been characterized by us in this study: Loss-
of-function alleles that abolish the activity of pdr-1, and in-
frame deletion alleles that generate truncated variants of PDR-1
that still retain the capability of interacting with their protein
partners, including CHN-1/CHIP. These alleles behave as gain-
of-misfunction alleles since they incorporate into the PDR-1/
CHN-1 ubiquitylation complex, but result in its inactivation.
The pdr-1 alleles tm395 and lg103 are representative alleles of
both classes. We crossed dys-1; hlh-1 double mutants with prd-
1(tm395) and pdr-1(lg103), respectively. The putative null
allele tm395 conferred a weakly significant suppression of
muscle degeneration (P=0.0081), whereas pdr-1(lg103) in dys-
1; hlh-1 background resulted in a significant improvement of
mobility (Pb0.001) (Fig. 2). Although these data do not
confidently prove a direct contribution of parkin to dys-1-dependent muscle degeneration, the strong suppression of the
gain-of-misfunction allele lg103 clearly indicates that the
combination of elimination of PDR-1 E3 ubiquitylation activity
(the deletion removes the ubiquitin-like domain) and sequestra-
tion of CHN-1 through the deleted PDR-1 together effectively
blocks muscle decay. Taken together, this result indirectly
verified the suppressor activity of chn-1 mutants.
The substrate degraded by the CHN-1/CHIP and PDR-1/
Parkin containing ubiquitylation complex is currently not
known. Potential candidates involve regulators of muscle
degradation of the subunits of the DGC, that, together with
other membrane components, have been proposed to be
destabilized as a result of dystrophin mutation (Wehling et al.,
2001). Future experiments should be designed to identify these
CHN-1/CHIP targets. Nevertheless, human CHIP might be an
attractive target to suppress Duchenne muscular dystrophy-
associated muscle degeneration, as no severe phenotypes have
been observed in mice deficient for CHIP function (Dai et al.,
2003). The dystrophin-mediated muscle degeneration in C.
elegans undoubtedly only represents a subset of aspects of the
clinical and physiological complexity observed in human
Fig. 5. Improvement of myosin patterning in dys-1; hlh-1mutants by chn-1mutation. Myosin heavy chain in body-wall muscle sarcomeres detected by a Pmyo-3MYO-
3∷GFP translational fusion: (a) wild type; (b–d), dys-1(cx18); hlh-1(cc561), disorganized, fraying myosin filaments and disintegrated muscle cells; (e, f) chn-1
(by155) dys-1(cx18); hlh-1(cc561), myosin filament organisation comparable to the wild type. All animals were maintained at 15 °C and were second-day adults at the
time point of experiment.
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(Hoppe et al., 2004) and the major components of the DGC
(Grisoni et al., 2002), together with the strong conservation of
the ubiquitin/proteasome protein degradation system and
several recently discovered similarities in response to genetic
and pharmacological interventions into the DMD model (Gaud
et al., 2004), suggest a similar role of CHIP in vertebrate
models. In such a case, our data suggested that selective
chemical inhibitors of muscle-specific protein degradation
could be effective in reducing muscle degeneration in DMD
patients.
Materials and methods
Strains
The general handlings of nematodes was done as previously described
(Brenner, 1974). The following strains were used: N2 Bristol (wild type), dys-
1(cx18)I (Bessou et al., 1998); hlh-1(cc561ts)II (Harfe et al., 1998); chn-1
(by155)I (Hoppe et al., 2004). dys-1(cx18)I; hlh-1(cc561)II (Gieseler et al.,
2000); ufd-2(tm1380)II (Janiesch et al., 2007); pdr-1(tm395)III and pdr-1
(lg103)III (Springer et al., 2005); PD4251 (ccIs4251 I; dpy-20(e1282) IV) (the
integrated array ccIs4251 is made up of three plasmids: pSAK4− myo-3
driving mitochondrially targeted GFP; pSAK2− myo-3 promoter driving
nuclear targeted GFP–LacZ fusion and a dpy-20 subclone) (Fire et al., 1998);RW1596 (myo-3(st386) V; stEx30) (Campagnola et al., 2002). PD4251 was
crossed with chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II and dys-1(cx18)I; hlh-
1(cc561)II to generate BR3403 chn-1(by155) dys-1(cx18)I ccIs4251 I; hlh-1
(cc561)II and BR3404 dys-1(cx18)I ccIs4251 I; hlh-1(cc561)II, respectively.
RW1596 was crossed with chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II and
dys-1(cx18)I; hlh-1(cc561)II to generate BR3370 chn-1(by155) dys-1(cx18)I;
hlh-1(cc561)II; stEx30 and BR3371 dys-1(cx18)I; hlh-1(cc561)II; myo-3
(st386) V; stEx30, respectively. chn-1(by155) dys-1(cx18)I and chn-1(by155)I;
hlh-1(cc561)II double mutants were obtained by crossing the corresponding
single mutants. chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II mutant was
obtained by crossing dys-1(cx18)II; hlh-1(cc561)II and chn-1(by155)I mutants.
dys-1(cx18)I; hlh-1(cc561) ufd-2(tm1380)II was obtained by crossing dys-1
(cx18)I; hlh-1(cc561)II with ufd-2(tm1380)II, dys-1(cx18)I; hlh-1(cc561)II;
pdr-1(tm395)III was obtained by crossing dys-1(cx18)I; hlh-1(cc561)II with
pdr-1(tm395)III. dys-1(cx18)I; hlh-1(cc561)II; pdr-1(lg103)III was obtained
by crossing dys-1(cx18)I; hlh-1(cc561)II with pdr-1(lg103)III. All strains were
maintained at 15 °C on standard NGM-agar plates seeded with E. coli strain
OP50.
Expression constructs and generation of transgenic animals
The 2.2-kb genomic coding sequence of chn-1 was amplified using
primers RB3540 (GCGGCCGCATGTCAAGCGGCGCCGAACA) and
RB3552 (GCGGTACCTTAAACCATGCCTCCGGGTT) and cloned between
NotI and KpnI in plasmid pBY2085, a derivative of pPD117.01 in which the
1.3 kb pan neuronal aex-3 promoter, amplified with primers BR3746
(CACGGCGGATCCAGCTTCCACAAAAACTGCCGCTTCAATTC) and
Fig. 6. Nomarski picture of mid-body region of 2-day-old adult dys-1(cx18);
hlh-1(cc561)ts mutant worms. Several muscle cells accumulated intracellular
vesicles typical for lysosomal disintegration seen during necrosis (indicated by
arrows). Membranes of some neighbouring cells are detached from each other
(indicated by arrowheads). Scale bar: 20 μm.
Fig. 8. MG132 treatment suppresses the motility defect of dys-1; hlh-1
dystrophic animals. Food race experiment of dys-1(cx18); hlh-1(cc561) and
N2 wild type animals. Second-day adult animals were treated either with
200 μM DMSO, 500 μM DMSO or with 1% DMSO (control) starting at larval
stage L2. P values indicate comparisons to dys-1(cx18); hlh-1(cc561) grown
on 1% DMSO. ∗∗∗Pb0.001. Error bars represent standard error of the mean
(SEM).
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was inserted between BamHI and NotI, resulting in pBY2330 (pBY2085-
Paex-3∷chn-1). The chn-1 sequence from plasmid pBY2330 was amplified
with primers RB3542 (GCTAGCATGTCAAGCGGCGCCGAACA) and
RB3552 and was subcloned between restriction sites NheI and KpnI of
plasmid pPD30.38, resulting in plasmid pBY2331, in which chn-1 is
expressed from the muscle-specific unc-54 promoter (pPD30.38-Punc-54∷chn-Fig. 7. Expression of chn-1 in the musculature is sufficient to rescue the chn-1
suppression of dystrophic animals. Loss of chn-1 in the musculature is
responsible for dys-1; hlh-1 suppression, since reintroduction of a chn-1
transgene expressed from the unc-54 muscle promoter, but not from the
neuron-specific aex-3 promoter, reverts this suppression. Motility of second-
day adult animals with different genetic backgrounds was measured. Full
genetic nomenclature of strains used: chn-1 dys-1; hlh-1: chn-1(by155) dys-1
(cx18); hlh-1(cc561). dys-1; hlh-1: dys-1(cx18); hlh-1(cc561). Transgenes
were constructed independently and consist of: byEx577 and byEx641: Ex
[Punc-54∷chn-1 Pmyo-3∷gfp Pmyo-2∷mCherry]. byEx644 and byEx584: Ex
[Paex-3∷chn-1 Paex-3∷gfp Pmyo-2∷mCherry]. Transgenic lines with muscle- or
neuron-specific chn-1 expression all carry the following genetic background:
chn-1(by155) dys-1(cx18); hlh-1(cc561). P values refer to comparisons with
dys-1(cx18); hlh-1(cc561). ns, not significant (P≥0.05), ∗∗∗Pb0.001. Error
bars represent standard error of the mean (SEM).1). The latter plasmids drive expression of chn-1 selectively in neurons
(pBY2330) or body-wall muscles (pBY2331) (data not shown).
Generation of transgenic lines
To generate transgenic lines, the following DNA mixtures were injected:
(A) Neuron-specific expression of chn-1: 1 ng/μl pBY2330 (pBY2085-
Paex-3∷chn-1), 5 ng/μl pBY2085 (Paex-3∷gfp); 20 ng/μl pBY2550
(Pmyo-2∷mCherry); were injected into chn-1(by155) dys-1(cx18)I; hlh-1
(cc561)II animals generating strain BR4294 chn-1(by155) dys-1(cy18)I;
hlh-1(cc561)II byEx584[Paex-3∷chn-1; Paex-3∷gfp; Pmyo-2∷mCherry].
1 ng/μl pBY2330 (pBY2085-Paex-3∷chn-1), 10 ng/μl pBY2085
(Paex-3∷gfp); 20 ng/μl pBY2550 (Pmyo-2∷mCherry); 40 ng/μl salmon
sperm DNA were injected into chn-1(by155) dys-1(cx18)I generating
strain BR4312 chn-1(by155) dys-1(cy18)I byEx644. Strain BR4312
was crossed with chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II to
generate strain BR4315 chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II
byEx644[Paex-3∷chn-1; Paex-3∷gfp; Pmyo-2∷mCherry].
(B) Muscle-specific expression of chn-1: 1 ng/μl pBY2331 (pPD30.38-
Punc-54∷chn-1); 10 ng/μl pPD114.95 (Pmyo-3∷gfp); 20 ng/ μl
pBY2550 (Pmyo-2∷mCherry); 70 ng/μl salmon sperm DNA was
injected in N2 animals; generating strain BR4287 byEx577. Strain
BR4287 was crossed first with chn-1(by155) dys-1(cy18)I and then
with hlh-1(cc561)II animals to generate strain BR4339 chn-1(by155) dys-
1(cy18)I; hlh-1(cc561)II byEx577[Punc-54∷chn-1; Pmyo-3∷gfp;
Pmyo-2∷mCherry]. 1 ng/μl pBY2331 (pPD30.38-Punc-54∷chn-1);
10 ng/μl pPD114.95 (Pmyo-3∷gfp); 20 ng/μl pBY2550 (Pmyo-2∷mCherry);
40 ng/μl salmon sperm DNA was injected in chn-1(by155) dys-1(cx18)
I generating strain BR4309 chn-1(by155) dys-1(cy18)I byEx641.
BR4309 was crossed with chn-1(by155) dys-1(cx18)I; hlh-1(cc561)II
to generate BR4316 chn-1(by155) dys-1(cy18)I; hlh-1(cc561)II
byEx641[P
unc-54
∷chn-1; Pmyo-3∷gfp; Pmyo-2∷mCherry].
Motility assay/Food race assay
The food race assay, a modified chemosensory assay, was used to analyze
locomotion. This experiment was carried out at 15 °C. 50 μl fresh OP50 was
dropped on one side of 5 cm NGM-agar plates and incubated at 37 °C. Before
the food race started the plates were incubated for 12 h at 15 °C.
Synchronized second-day adult animals were washed off the plates with
pre-chilled M9 buffer. After 2 quick washes worms were dropped in 20 μl M9
buffer on the NGM-agar plates, on the opposite side of the bacteria (OP50).
The time count started when the M9 buffer was soaked into the agar. After
201O. Nyamsuren et al. / Developmental Biology 312 (2007) 193–202defined time periods, the percentage of the worms that reached the food was
calculated.
The motility assay used to determine the speed of individual animals was
carried out at 15 °C. Synchronized second day adult wild type and mutants
animals were washed off the plates with pre-chilled M9 buffer. After 2 quick
washes worms with M9 animals were dropped in 20 μl M9 buffer on prechilled
NGM-agar plates without OP50. Plates were left for 45 min to dry and for
acclimatisation of the worms. Movies of animals were recorded using
QuickTimeVideo with a Dolphin F145B video camera (Allied Technology)
mounted on a Leica MZ75 dissecting microscope. Videos were analyzed with
the DIAS 3.4.2 software (Solltech Inc.) using the “Centroid, Centre of Area”
method. Every Movie (15 frames/s) consists of 151 frames (10.1 s duration).
Only video captures, in which worms moved unidirectional and constantly for
the entire period of 151 frames, were considered for the analysis.
Statistical analyses
One-way ANOVA was used to test statistical differences between
independent groups within the same experiment. Statistical significance was
tested with Newman–Keuls, Tukey and Bonferroni post tests. Two-tailed
unpaired Student's t-test has been used to examine direct differences between
independent groups and to validate ANOVA results.
Phalloidin staining
Phalloidin staining was carried out as described in Waterston et al. (1984).
Synchronized, second-day adult worms were fixed in 3% formaldehyde,
extracted with acetone at −20 °C, and incubated in 3 U of phalloidin Alexa
Fluor® 488 (Molecular Probes) for 2 h. Imager Z1 microscope and Axiovision
software version 4.3 (both Carl Zeiss, Goettingen, Germany) were used for all
microscopic observations and documentations. All worms analyzed were 2-day-
old adult hermaphrodites.Acknowledgments
We thank Britta Spanier, Anne Oelmann and Angelika
Schaefer for the help with the experiments, Thorsten Hoppe and
Laurent Segalat for critical comments and discussions, the C.
elegans Genetics Center for providing PD4251; RW1596
strains, Laurent Segalat for the dys-1(cx18) and Brian Harfe
for the hlh-1(cc561) mutants, and R. Tsien for the pRSET-B-
mCherry plasmid. Work in the lab of RB was supported by the
European Union (Network of Excellence LIFESPAN), the
Fonds der Chemischen Industrie, the “Qualitaetsoffensive
Programm” of the State of Baden-Württemberg and the German
Research Council (DFG CRC592 and RTG1104).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ydbio.2007.09.033.
References
Adachi, H., Waza, M., Tokui, K., Katsuno, M., Minamiyama, M., Tanaka, F.,
Doyu, M., Sobue, G., 2007. CHIP overexpression reduces mutant androgen
receptor protein and ameliorates phenotypes of the spinal and bulbar
muscular atrophy transgenic mouse model. J. Neurosci. 27, 5115–5126.
Ballinger, C.A., Connell, P., Wu, Y., Hu, Z., Thompson, L.J., Yin, L.Y.,
Patterson, C., 1999. Identification of CHIP, a novel tetratricopeptide repeat-
containing protein that interacts with heat shock proteins and negatively
regulates chaperone functions. Mol. Cell. Biol. 19, 4535–4545.Bessou, C., Giugia, J.B., Franks, C.J., Holden-Dye, L., Segalat, L., 1998.
Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to
hyperactivity and suggest a link with cholinergic transmission. Neurogenetics
2, 61–72.
Bonuccelli, G., Sotgia, F., Schubert, W., Park, D.S., Frank, P.G., Woodman,
S.E., Insabato, L., Cammer, M., Minetti, C., Lisanti, M.P., 2003.
Proteasome inhibitor (MG-132) treatment of mdx mice rescues the
expression and membrane localization of dystrophin and dystrophin-
associated proteins. Am. J. Pathol. 163, 1663–1675.
Brenner, S., 1974. The genetics of Caenorhabditis elegans. Genetics 77, 71–94.
Bulfield, G., Siller, W.G., Wight, P.A., Moore, K.J., 1984. X chromosome-
linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci.
U. S. A. 81, 1189–1192.
Campagnola, P.J., Millard, A.C., Terasaki, M., Hoppe, P.E., Malone, C.J.,
Mohler, W.A., 2002. Three-dimensional high-resolution second-harmonic
generation imaging of endogenous structural proteins in biological tissues.
Biophys. J. 82, 493–508.
Dai, Q., Zhang, C., Wu, Y., McDonough, H., Whaley, R.A., Godfrey, V., Li,
H.H., Madamanchi, N., Xu, W., Neckers, L., Cyr, D., Patterson, C., 2003.
CHIP activates HSF1 and confers protection against apoptosis and cellular
stress. EMBO J. 22, 5446–5458.
Ervasti, J.M., Campbell, K.P., 1991. Membrane organization of the dystrophin–
glycoprotein–complex. Cell 66, 1121–1131.
Ervasti, J.M., Campbell, K.P., 1993. A role for the dystrophin–glycoprotein–
complex as a transmembrane linker between laminin and actin. J. Cell Biol.
122, 809–823.
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C.,
1998. Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature 391, 806–811.
Gaud, A., Simon, J.M., Witzel, T., Carre-Pierrat, M., Wermuth, C.G., Segalat,
L., 2004. Prednisone reduces muscle degeneration in dystrophin-deficient
Caenorhabditis elegans. Neuromuscul. Disord. 14, 365–370.
Gieseler, K., Grisoni, K., Segalat, L., 2000. Genetic suppression of phenotypes
arising from mutations in dystrophin-related genes in Caenorhabditis
elegans. Curr. Biol. 10, 1092–1097.
Grisoni, K., Martin, E., Gieseler, K., Mariol, M.C., Segalat, L., 2002. Genetic
evidence for a dystrophin–glycoprotein–complex (DGC) in Caenorhabditis
elegans. Gene 294, 77–86.
Harfe, B.D., Branda, C.S., Krause, M., Stern, M.J., Fire, A., 1998. MyoD
and the specification of muscle and non-muscle fates during
postembryonic development of the C. elegans mesoderm. Development
125, 2479–2488.
Herndon, L.A., Schmeissner, P.J., Dudaronek, J.M., Brown, P.A., Listner, K.M.,
Sakano, Y., Paupard, M.C., Hall, D.H., Driscoll, M., 2002. Stochastic and
genetic factors influence tissue-specific decline in ageing C. elegans. Nature
419, 808–814.
Hoppe, T., Cassata, G., Barral, J.M., Springer, W., Hutagalung, A.H., Epstein,
H.F., Baumeister, R., 2004. Regulation of the myosin-directed chaperone
UNC-45 by a novel E3/E4-multiubiquitylation complex in C. elegans. Cell
118, 337–349.
Imai, Y., Soda, M., Hatakeyama, S., Akagi, T., Hashikawa, T., Nakayama, K.I.,
Takahashi, R., 2002. CHIP is associated with Parkin, a gene responsible for
familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol.
Cell 10, 55–67.
Janiesch, P.C., Kim, J., Mouysset, J., Barikbin, R., Lochmüller, H., Cassata,
G., Krause, S., Hoppe, T., 2007. The ubiquitin-selective chaperone CDC-
48/p97 links myosin assembly to human myopathy. Nat. Cell Biol. 9,
379–390.
Karpati, G., Carpenter, S., Prescott, S., 1988. Small-caliber skeletal muscle
fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 11,
795–803.
Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H.D., Mayer, T.U., Jentsch, S.,
1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain
assembly. Cell 96, 635–644.
Lecker, S.H., Solomon, V., Mitch, W.E., Goldberg, A.L., 1999. Muscle protein
breakdown and the critical role of the ubiquitin–proteasome pathway in
normal and disease states. J. Nutr. 129, 227S–237S.
Mariol, M.C., Martin, E., Chambonnier, L., Segalat, L., 2007. Dystrophin-
202 O. Nyamsuren et al. / Developmental Biology 312 (2007) 193–202dependent muscle degeneration requires a fully functional contractile
machinery to occur in C. elegans. Neuromuscul. Disord. 17, 56–60.
McKay, S.J., Johnsen, R., Khattra, J., Asano, J., Baillie, D.L., Chan, S., Dube,
N., Fang, L., Goszczynski, B., Ha, E., Halfnight, E., Hollebakken, R.,
Huang, P., Hung, K., Jensen, V., Jones, S.J., Kai, H., Li, D., Mah, A., Marra,
M., McGhee, J., Newbury, R., Pouzyrev, A., Riddle, D.L., Sonnhammer, E.,
Tian, H., Tu, D., Tyson, J.R., Vatcher, G., Warner, A., Wong, K., Zhao, Z.,
Moerman, D.G., 2003. Gene expression profiling of cells, tissues, and
developmental stages of the nematode C. elegans. Cold Spring Harbor
Symp. Quant. Biol. 68, 159–169.
Megeney, L.A., Kablar, B., Perry, R.L., Ying, C., May, L., Rudnicki, M.A.,
1999. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc.
Natl. Acad. Sci. U. S. A. 96, 220–225.
Pickart, C.M., Eddins, M.J., 2004. Ubiquitin: structures, functions, mechanisms.
Biochim. Biophys. Acta 1695, 55–72.Rosser, M.F., Washburn, E., Muchowski, P.J., Patterson, C., Cyr, D.M., 2007.
Chaperone functions of the E3 ubiquitin ligase CHIP. J. Biol. Chem. 282,
22267–22277.
Springer, W., Hoppe, T., Schmidt, E., Baumeister, R., 2005. A Caenorhabditis
elegans Parkin mutant with altered solubility couples alpha-synuclein
aggregation to proteotoxic stress. Hum. Mol. Genet. 14, 3407–3423.
Syntichaki, P., Tavernarakis, N., 2002. Death by necrosis. Uncontrollable
catastrophe, or is there order behind the chaos? EMBO Rep. 3,
604–609.
Waterston, R.H., Hirsh, D., Lane, T.R., 1984. Dominant mutations affecting
muscle structure in Caenorhabditis elegans that map near the actin gene
cluster. J. Mol. Biol. 180, 473–496.
Wehling, M., Spencer, M.J., Tidball, J.G., 2001. A nitric oxide synthase
transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155,
123–131.
